N4-Benzoylcytosine CAS 26661-13-2 Purity ≥99.0% Sofosbuvir Intermediate Factory

Short Description:

Name: N4-Benzoylcytosine

CAS: 26661-13-2

Appearance: White or Off-White Powder

Purity: ≥99.0% (HPLC)

Intermediate of Sofosbuvir (CAS: 1190307-88-0) in the treatment of Hepatitis C Virus (HCV)

High Quality, Commercial Production

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Sofosbuvir Related Intermediates:

Sofosbuvir	CAS: 1190307-88-0
N4-Benzoylcytosine	CAS: 26661-13-2
2-(triphenyl-phosphanylidene)-propionic acid ethyl ester	CAS: 21382-82-1
Pentafluorophenol	CAS: 771-61-9

26661-13-2 - Chemical Properties:

Name	N4-Benzoylcytosine
CAS Number	26661-13-2
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C11H9N3O2
Molecular Weight	215.21
Density	1.33±0.10 g/cm3
Melting Point	>300℃(dec.) (lit.)
COA & MSDS	Available
Origin	Shanghai, China
Shelf Life	36 Months if Stored Properly
Brand	Ruifu Chemical

26661-13-2 - Specifications:

Item	Specifications
Appearance	White or Off-White Powder
Identification	HPLC
Purity / Analysis Method	≥99.0% (HPLC)
Moisture (K.F)	≤0.50%
Loss on Drying	≤0.50%
Residue on Ignition	≤0.50%
Cytosine	≤0.50%
Heavy Metals	≤20ppm
Test Standard	Enterprise Standard
Application	Intermediate of Sofosbuvir (CAS: 1190307-88-0)

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture

Advantages:

FAQ:

26661-13-2 - Risk and Safety:

Hazard Symbols Xi - Irritant
Risk Codes R20/22 - Harmful by inhalation and if swallowed.
R36/37/38 - Irritating to eyes, respiratory system and skin.
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36 - Wear suitable protective clothing.
WGK Germany 3
HS Code 2933599099

26661-13-2 - Application:

Sofosbuvir (CAS: 1190307-88-0) is a drug used for the treatment of hepatitis C. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C.